Physician profile
Syed Rizvi
NPI 1598840399
$1,754.53
in general payments reported to CMS, 2019-2025
18 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2022: $95.92 · 2023: $302 · 2024: $230 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $244.16 | 2019 | |
| Pfizer INC. | $232.57 | 2019 | |
| Abbvie INC. | $201.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $180.26 | 2023-2025 | Cuvitru, Eohilia, Takhzyro |
| Glaxosmithkline, LLC. | $114.75 | 2023 | Benlysta |
| Emd Serono, INC. | $114.42 | 2019 | |
| Genzyme Corporation | $109.48 | 2019 | |
| Radius Health, INC. | $93.66 | 2019 | |
| Capsovision, INC. | $90.23 | 2025 | Capsocam Plus |
| Regeneron Healthcare Solutions, INC. | $79.47 | 2023-2024 | Dupixent |
| Amgen INC. | $70.00 | 2022 | |
| Octapharma USA, INC. | $65.44 | 2023 | Cutaquig |
| Beigene USA, INC. | $49.02 | 2024 | Brukinsa |
| Csl Behring | $34.79 | 2023 | Haegarda |
| Biotronik INC. | $25.92 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $21.68 | 2023 | Coagadex, Gammaplex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.53 | 2023 | Trulance, Xifaxan |
| Astrazeneca Pharmaceuticals LP | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.